0001193125-19-001043 Sample Contracts

SUBLICENSE AGREEMENT by and among CHONGQING TAIHAO PHARMACEUTICAL CO LTD, CHONGQING JINGDONG JUNZHUO PHARMACEUTICAL CO., LTD. and ATHENEX, INC. December 30, 2018

Sublicense Agreement • January 3rd, 2019 • Athenex, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Sublicense Agreement
• Filed
  January 3rd, 2019
• Company
  Athenex, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SUBLICENSE AGREEMENT (this “Sublicense Agreement”) is made as of December 30, 2018 (the “Effective Date”), by and among Chongqing Taihao Pharmaceutical Co Ltd,, a company organized and existing under the laws of China and having its principal office at C—5 #105 C-5, Er Lang Chuang Ye Road, Jiulongpo District, Chongqing, China (“Sublicensor” or “Taihao”), Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd, a company organized and existing under the laws of China and having its principal office at 26# West Honghu Road Yubei District, Chongqing, China (“Sublicensee” or “Jingdong”) and solely for purposes of Section 10.13 herein, Athenex, Inc., a company organized and existing under the laws of the State of Delaware and having its principal office at Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York, 14203 (“Athenex” and together with Sublicensor and Sublicensee, the “Parties” and each individually, a “Party”).

LICENSE AGREEMENT by and between ATHENEX, INC. and CHONGQING TAIHAO PHARMACEUTICAL CO LTD December 30, 2018

License Agreement • January 3rd, 2019 • Athenex, Inc. • Pharmaceutical preparations • New York

• Contract Type
  License Agreement
• Filed
  January 3rd, 2019
• Company
  Athenex, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS LICENSE AGREEMENT (this “License Agreement”) is made as of December 30, 2018 (the “Effective Date”), by and between Athenex, Inc., a company organized and existing under the laws of the State of Delaware and having its principal office at Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York, 14203 (“Licensor” or “Athenex”) and Chongqing Taihao Pharmaceutical Co Ltd, a company organized and existing under the laws of China and having its principal office at C—5 #105 C-5, Er Lang Chuang Ye Road, Jiulongpo District, Chongqing, China (“Licensee” or “Taihao” and together with Licensor, the “Parties” and each individually, a “Party”).